Stratolaunch successfully completed its hypersonic test flight earlier this year. Image courtesy of Draper

With a recent air-launched test vehicle flight that came close to hypersonic speed, research company Draper has accelerated the potential for its flight technology.

Draper, a Cambridge, Massachusetts-based nonprofit, provided the crucial guidance, navigation, and control flight software for the flight. That guidance system was built on the same Draper technology that NASA has used in its Apollo mission, the international space station and space shuttle programs.

“In a broad sense, Draper has been working hypersonic since Apollo,” Rick Loffi, space systems program manager and lead executive for Draper’s Houston campus, tells InnovationMap.

The navigation software controlled the first powered test flight of an air-launched vehicle that approached the hypersonic threshold of Mach 5, or 3,800 miles per hour, or five times the speed of sound.

Stratolaunch successfully completed the flight of its TA-1 Talon test vehicle in the Mojave Desert in March. The California-based company designs and launches aerospace vehicles and technologies, providing access to a reusable hypersonic testing platform, according to its website. The historic test flight landed in the Pacific Ocean, and achieved successful ignition, acceleration and sustained altitude climb.

“The Draper software is really what’s stabilizing the vehicle during flight…and controlling it as it gets up into altitude and speed,” Brandon Jalbert, space systems program manager for Draper and team lead for Stratolaunch, says “so it’s not doing loop-de-loops, or getting unstable…blowing up in the atmosphere.”

Draper uses model-based design and algorithms in its software, and for the boost phase of the Talon test, Draper developed a novel algorithm, which built upon its previous work for NASA, Jalbert says.

Aerospace manufacturing companies like Boom and Hermeus stand poised to pick up where the Concorde left off, and are racing to implement and execute on accessible hypersonic and supersonic commercial technology.

The Concorde aircraft made supersonic, four-hour transoceanic flights a reality, but only for the very wealthy, and shut down in 2003.

Draper is not involved in any of those ventures to bring accessible supersonic flight back to the skies. Its primary focus with hypersonic will remain with deterrence and testing platforms, Jalbert says.

But the company’s technology “has applications everywhere from military to commercial activity,“ he says.

“Our focus is to solve complex challenges of national importance,” he says, “whether that’s…helping our commercial partners, or working on civil or military applications. That’s where we see ourselves being of value to the industry.”

With the harsh conditions involved in hypersonic flight, advancing the technology has its challenges.

“You’ve got to have proper hardware and electronics and sensors that can operate within those conditions,” Jalbert says.

Draper originated in 1932 when engineer Charles Stark Draper founded what eventually became the Instrumentation Lab at MIT.

His work on inertial navigation theory paved the way for the use of the autopilot in today’s commercial jets. The lab was divested by MIT in the 1970s, and became a nonprofit. Draper has long been a government contractor and has worked on many military projects, dating to WWII.

Draper in 2023 secured the $2.2 billion renewal of a long-standing contract with the U.S. Navy to provide the guidance system for the submarine-launched Trident II D-5 missile.

The U.S. government has shown a growing interest in the development of hypersonic weapons systems, as Russia and China have developed advanced capabilities.

The Pentagon’s budget request for hypersonic research for fiscal year 2025 was $6.9 billion, up from $4.7 billion for 2023, according to a recent U.S. Naval Institute report.

“There’s a big shift, in deterrence, as well as offensive, on hypersonic,” Jalbert says.

However, the Defense Department has not yet acquired hypersonic weapons, according to the report, but is developing prototypes and testing.

Draper has a long, celebrated history with NASA, and its Houston office is housed at Johnson Space Center. Draper's presence in Houston dates back to the 1960s, Loffi says.

From the Apollo missions to the space station and now the Artemis program, which aims to land the first person of color and the first woman on the moon by 2026 on its Orion spacecraft, Draper has partnered with NASA every step of the way, providing its navigation system for space flight.

“Right now, our biggest customer within NASA is the Orion program,” Loffi says, with approximately 15 of the 20-person Houston office working on the project, in collaboration with the company’s Cambridge colleagues.

Draper's Houston office is working on NASA's Orion program. Photo via NASA

The company is also working with NASA on lunar landing technology and sub-orbital experiments, as well as the propulsion element and Gateway space station for Artemis.

Amazon founder Jeff Bezos’s aerospace manufacturing company Blue Origin is also partnering with Draper to develop the Artemis human landing system.

Neither Loffi nor Jalbert aspired to go into outer space themselves, but rather to provide solutions to make that possible. Human spaceflight has been a lifelong passion for Loffi.

While he had lots of job opportunities after graduating from Purdue University with a degree in electrical engineering, Loffi chose NASA.

“I wasn’t that person who grew up dreaming of becoming an astronaut,” Loffi says. “I was old enough to see the Apollo 11 moon landing, and it did inspire me.”

His work at NASA began after the space shuttle Challenger explosion, in 1986. He was part of the agency’s effort to return to space flight, and worked on space station development, before joining Draper in 2011.

Jalbert, a graduate of Northeastern University, says his early work at Draper “lit the fires for my interest in space.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

3 Houston incubators and accelerators fueling the growth of local startups

Meet the finalists

It takes a village to launch a business. That's where Houston's network of incubators and accelerators can step in, providing the resources, mentorship and community needed to push a fledgling company forward.

As part of our 2026 Houston Innovation Awards, the Incubator/Accelerator of the Year category honors a local organization that is championing and fueling the growth of Houston startups.

Three incubators and accelerators have been named finalists for the 2026 award. They support startups ranging from hard-tech companies to food and youth concepts.

Read more about these organizations below. The 2026 winners will be announced on InnovationMap.com in mid-November.

Activate

Hard tech incubator Activate supports scientists in "the outset of their entrepreneurial journey." The Houston hub was introduced in 2024, and joins others in Boston, New York, and Berkley, California—where Activate is headquartered. It named its third Houston cohort this summer.

The two-year program graduated its first class of Houston fellows in 2026 and saw its first alumni IPO from Houston-based Fervo Energy, which previously participated in a Berkley cohort. Nationally, it has supported 346 fellows and 276 companies since 2015. Those companies have raised more than $6 billion in follow-on funding, according to Activate. In Houston, it has supported Houston startups like Solidec, FlowCellutions and Orbital Arc. Activate Houston is led by managing director Jeremy Pitts, who co-founded Greentown Labs in Boston. It is based out of the Ion.

Impact Hub Houston

Impact Hub Houston supports early-stage ventures at various stages of development through innovative programs that address pressing societal issues. The nonprofit organization supports social impact startups through mentorship, connections and training opportunities.

There are more than 110 Impact Hubs globally with members spanning 72 countries. Launched in 2018, Impact Hub Houston says its membership tripled by the beginning of 2026. This year brought major milestones for the community, including the launch of its Ideas to Impact Accelerator, which supported 11 founders across the health, education, food systems, civic technology and workforce development sectors. It also received funding from more than 20 international Impact Hubs to develop SYNC, a collaboration platform that 25 Impact Hubs across five continents have committed to pilot. The organization has worked with local startups including Myoviva Health, The Change Lab and INNERVERSE Inc.

MarMo Innovation

Galveston-based business incubator MarMo Innovation is focused on removing barriers to entrepreneurship. It aims to provide affordable space, education, mentorship, market access, connections and real-world opportunities that help entrepreneurs move from idea to launch to sustainable growth. The "industry-agnostic" incubator was founded in 2022 and is led by Executive Director Erica Delgadillo.

This year, the organization moved from primarily serving as a coworking and community space into a more comprehensive entrepreneurial incubator by expanding its MarMo Market, MarMo Market Jr. and Lunch LineUp programs. A major focus for MarMo is food entrepreneurship. It is developing an Incubator Kitchen, which MarMo says will support programs like its Cottage to Commercial Bootcamp and Food Biz 101. The organization also expanded its board this year and says it is diversifying its revenue through memberships, events, markets, equipment and space rentals, sponsorships, grants and new entrepreneurial programming.

Baylor College of Medicine launches VC fund to invest in biotech startups

fresh funding

Houston’s Baylor College of Medicine just unveiled a new venture capital fund that backs early-stage biotech startups—and it’s already made its first investment.

BCM Legacy Fund I, funded by philanthropies, invested an undisclosed amount in Houston biotech startup Nemea Therapeutics. Nemea, a spinout of the Baylor College of Medicine and Germany’s Lead Discovery Center, is developing an oral drug to treat metastatic triple-negative breast cancer that no longer responds to currently available therapies.

This type of aggressive cancer spreads from the breast to other areas of the body, such as the bones, liver, lungs or brain. Roughly 38,000 to 57,000 Americans are diagnosed each year with metastatic triple-negative breast cancer. One study showed about half of patients survive past the one-year mark following diagnosis and about one-third survive two years.

“Baylor College of Medicine’s laboratories produce discoveries with the potential to change patients’ lives, and too many of them stall where academic funding ends and private investment has not yet begun,” Dr. Jakub Tolar, president, CEO and executive dean of the Baylor College of Medicine, said in a press release. “The BCM Legacy Fund fills that gap, giving our scientists a path to advance their discoveries to patients.”

The National Institutes of Health awards more than $36 billion per year for biomedical research in the U.S., Baylor said. But some biomedical discoveries “never leave the starting line because they don’t yet fit the economics of venture capital,” the college said.

“The forefront of a new model”

The BCM Legacy Fund aggregates philanthropic capital from private foundations and donor-advised funds. It then invests in startups so they can move beyond that starting line and into later-stage investment rounds. The Greater Houston Community Foundation is the fund’s philanthropic partner.

“It’s exciting to be on the forefront of a new model for philanthropic capital,” said Houston entrepreneur and investor Burton Hanson, managing partner of the fund.

“Not only do we hope to solve a real problem by advancing these therapies to the patients who need them most, but we also hope this model will inspire others in the city and beyond toward philanthropic creativity and a posture of ‘I sacrifice; we win.’”

The fund expects to invest in about 15 early-stage startups over a five-year span. Baylor declined to divulge the amount of money in the fund and the size of the investment in Nemea.

Nemea’s “world-class chemistry”

Hanson oversees the Baylor fund alongside Chicago investor Steve Lehmann, who led the University of Chicago’s Innovation Fund.

Lehmann said Nemea, the fund’s first portfolio company, “has world-class chemistry, Baylor biology, and patients with no good options. Our job is to fund the experiments that carry it to the next handoff, so that industry and later-stage investors can take it from there.”

Based at Houston’s massive Texas Medical Center, Nemea plans to start clinical trials next year in collaboration with Baylor’s Lester and Sue Smith Breast Center.

Nemea previously received $9 million from the Lead Discovery Center and a $1.6 million grant from Baylor. Last year, the startup said it was seeking $25 million to $30 million in seed and Series A funding.

Debra McCoy of Houston, a former managing director at BlackRock and former partner at Bain & Co., and Paul Thomas, co-founder and CEO of Spring-based benefits manager Luscinia Health, sit on the Baylor fund’s governing board. Dr. Paul Klotman, former president, CEO and executive dean of Baylor, is a senior strategic adviser.

How does the fund find investment targets?

The Baylor Legacy Fund relies on two tools to help unearth early-stage biotech startups:

  • High-resolution “innovation maps” of research institutions. These maps surface hidden clusters of innovation, identify rising-star researchers and tie pockets of “innovation supply” at Baylor to areas of “innovation demand” in biotech.
  • AI-enhanced due diligence. AI agents assist with due diligence of early-stage biotech startups. The fund says the platform “distills the frameworks we’ve developed over a decade of teaching and investing into a flexible … diligence environment.”

MD Anderson unveils $3.4B expansion with two new Houston cancer care facilities

major expansion

The cutting edge of cancer-fighting technology and science is getting even sharper after MD Anderson announced last week that it will open two new facilities in the Texas Medical Center within the next five years. Inspiration Tower and Prism will expand MD Anderson’s annual patient load in the TMC to 250,000 annually and will incorporate a variety of new techniques.

The $3.4 billion project will add 2 million square feet to MD Anderson's TMC footprint, bringing its total campus size to 22 million square feet by 2032. Located at the corner of Fannin Street and Holcombe Boulevard, the cancer center says the two new facilities will serve as its new "front door" to the TMC.

“Every detail of these buildings, from the technology to the treatment rooms, was designed around our patients who will receive their care in them and our employees who will work in them. The facilities will serve as a physical representation of hope for the patients and their families who will walk through the doors,” Dr. Jeffrey E. Lee, president ad interim of UT MD Anderson, said in a news release. “Inspiration Tower and Prism are the future of cancer care, and we are grateful for the longstanding support and guidance we’ve received from the UT System Board of Regents to bring these projects to life. These facilities are part of the most impactful capital expansion in UT MD Anderson’s history.”

Prism is especially exciting as it will represent fully half of the linear accelerator treatment in the TMC. Linear accelerator is a radiation treatment that uses magnetically charged fields to deliver targeted external radiation therapy, like shooting cancer with a rail gun. The treatment is safer and has fewer side effects than older radiation treatments.

In addition, Prism will contain 12 MRI machines, four CT scanners, two PET-CT units, 18 radiation vaults and seven radiation simulators. Patient comfort has also been put at a premium with multiple gardens and roof overlooks.

“Every patient we treat deserves an environment that reflects the excellence of the care they receive at UT MD Anderson,” Chris McKee, executive vice president and chief strategy officer at UT MD Anderson, added in the release. “Our new facilities will be innovative, agile, adaptable and beautiful, and they will allow us to care for more patients, more effectively – in an environment that enhances healing and well-being. We are building for our future and for every patient who will be counting on us.”

Prism is slated to open in 2030.

Inspiration Tower will have 25 floors of surgical, diagnostic, and treatment services. At 1.4 million square feet, it’s currently expected to be the largest cancer-specific treatment facility in the United States. The tower will be divided into units for specific types of cancer, making it easy to integrate the advancing research being done all over Houston.

Like Prism, Inspiration Tower is specifically designed to offer comfort and reassurance, with more garden space, terraces, and beautiful scenery to ease patient distress. It is expected to open in 2032.